Abstract | INTRODUCTION: METHODS: Patients with chemo-naïve stage IIIB/IV non-small cell lung cancer were randomized into two treatment arms. Patients were given oral S-1 (60 mg/m/d, twice a day) from days 1 to 14 with gemcitabine (1000 mg/m/d) on days 1 and 8 (arm A) or on days 8 and 15 (arm B). This cycle was repeated every 21 days. RESULTS: A total of 80 patients were entered in this trial. The primary end point of this study was response rate. The response rates of arm A and arm B were 22.0 and 28.9%, respectively (p = 0.606). Median time to treatment failure in arm A was 3.6 months and 4.8 months in arm B. Median time to progression in arm A was 4.1 months and 5.5 months in arm B. Median survival time in arm A and arm B was 15.5 months and 18.8 months, respectively. The toxicity profile was relatively mild and did not differ very much between two arms. CONCLUSION: The combination of gemcitabine and S-1 was determined to be feasible and effective for advanced non-small cell lung cancer. We selected arm B for further studies because of its higher response rate and survival data.
|
Authors | Miyako Satouchi, Yoshikazu Kotani, Nobuyuki Katakami, Temiko Shimada, Yoshiko Urata, Sho Yoshimura, Yasuhiro Funada, Akito Hata, Masahiko Ando, Shunichi Negoro |
Journal | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
(J Thorac Oncol)
Vol. 5
Issue 5
Pg. 696-701
(May 2010)
ISSN: 1556-1380 [Electronic] United States |
PMID | 20147856
(Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study, Randomized Controlled Trial)
|
Chemical References |
- Drug Combinations
- Deoxycytidine
- S 1 (combination)
- Tegafur
- Oxonic Acid
- Gemcitabine
|
Topics |
- Adenocarcinoma
(drug therapy, pathology)
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Carcinoma, Non-Small-Cell Lung
(drug therapy, pathology)
- Carcinoma, Squamous Cell
(drug therapy, pathology)
- Deoxycytidine
(administration & dosage, analogs & derivatives)
- Drug Combinations
- Female
- Humans
- Lung Neoplasms
(drug therapy, pathology)
- Male
- Neoplasm Staging
- Oxonic Acid
(administration & dosage)
- Safety
- Survival Rate
- Tegafur
(administration & dosage)
- Treatment Outcome
- Gemcitabine
|